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Abstract
Endoscopic ultrasound (EUS) is an inevitable tool for locoregional staging of upper gastrointestinal, rectal, and pancrea-
ticobiliary cancer. Transabdominal ultrasound (TUS) and computed tomography (CT) are the most important methods
used for the detection of liver metastases and other distant metastases. However, despite its limited operation range, EUS
and EUS-guided ﬁne-needle biopsy (EUS-FNB) may add value to TUS and CT by detecting and proving ‘occult’ liver
metastases and malignant ascites as well as nonregional lymph node metastases, adrenal metastases, and pleural carcinosis
in approximately 5–20% of cases of pancreaticobiliary and upper gastrointestinal tract cancer. This article is part of an
expert video encyclopedia.
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Materials
• Radial echoendsocope: EG-3670 URK; Pentax Europe
GmbH, Hamburg, Germany or longitudinal echoendo-
scope: EG-3870 UTK; Pentax Europe GmbH, Hamburg,
Germany.
• High-end ultrasound platform: HI vision Preirus; Hitachi
Medical Systems, Wiesbaden, Germany.
• 22-gauge endoscopic ultrasound-guided ﬁne-needle aspir-
ation (EUS-FNA) needles; Olympus Medical Hamburg,
Germany; Mediglobe, Achenmu¨hle, Germany.
• SonoVues; Bracco Imaging Deutschland, Konstanz, Germany.
Background and Endoscopic Procedure
The ideal pretherapeutic cancer staging strategy provides re-
liable information on both locoregional and distant tumor
spread. Guidelines recommend computed tomography (CT)
and transabdominal ultrasound (TUS) as the most important
methods for the detection of liver metastases and other distant
metastases in pancreaticobiliary and upper gastrointestinal
tract cancer (M-staging).1–4 The role of EUS in most guidelines
is conﬁned to locoregional staging.1,2,4 Despite the high sen-
sitivity of CT in detecting liver metastases and malignant
ascites, due to limited spatial resolution of CT, liver and ad-
renal metastases o10 mm, small nonregional lymph nodes
metastases (e.g., in the mediastinum) and very small amounts
of ascites may escape detection in cancer patients. EUS has
been shown to be very sensitive in detecting peritoneal ﬂuid of
only several milliliters and also liver metastases down to
o5 mm, which are not detectable by CT.5–7 However, EUS is
not capable of visualizing the whole liver and all mediastinal,
retroperitoneal, and visceral lymph node stations. Several
studies have shown a high clinical impact of EUS and EUS-
FNA in patients with esophageal, gastric, and pancreatic can-
cer, far beyond the classiﬁcation of T-stage and N-stage.8 In a
recent study in patients with gastric cancer, EUS demonstrated
suspected distant metastases in 35% of patients, and EUS-FNA
proved distant spread ultimately in 16.2% of patients.9 The
most frequent locations of distant metastases in this study
were mediastinal lymph nodes (65.6%), followed by non-
regional abdominal lymph nodes (11.5%), liver metastases
(9.8%), malignant ascites (6.6%), and adrenal or omental
metastases (each 1.2%). As judged by the board of surgeons,
EUS-FNA resulted in a change in the planned management in
14.5% of gastric cancer patients undergoing EUS, avoiding
unnecessary surgery and indicating palliative treatment.9 Very
similar results have been reported for patients with gastric,
esophageal, pancreatic, and pancreaticobiliary cancers: in ap-
proximately 5–20% of cases distal metastatic spread was
proved by EUS and EUS-FNA, changing management plans in
most cases.10–13 Patients with EUS-FNA-proven distant me-
tastases of upper gastrointestinal and pancreaticobiliary cancer
have a very poor prognosis.6,14 Therefore, in those patients,
surgical exploration and further imaging should be avoided
and palliative treatment should be initiated without delay.
Beyond pretherapeutic M-staging, EUS and EUS-FNA may
play a pivotal role in detecting and diagnosing recurrence or
late distant spread of gastrointestinal cancer.15–19 Owing to
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recent progress in palliative treatment, especially of colorectal
and gastric cancer, this strength of EUS-FNA should be
widely used.
Pitfalls
• False-positive ﬁndings of EUS-FNA are reported to occur in
approximately 1.1–2.2% of pancreatic cancers and in up to
7.6% of gastric and esophageal cancers.20,21 They are due
to:
J Tumor cell contamination of gastrointestinal ﬂuid.22,23
J Inadvertent needle passage through the primary tumor
of the gastrointestinal wall (e.g., gastric cancer).24
J Inappropriate biopsy sequence.8
• Nondiagnostic biopsies or false-negative ﬁndings are due
to technical failure, sampling error, or interpretation error.
Dependent in particular from target tissue, false-negatives
may occur in up to 20% of cases.8
Key Learning Points/Tips and Tricks
• In 5–20% of pancreaticobiliary and upper gastrointestinal
cancers, hitherto unrecognized systemic malignant disease
is detected by systematic EUS examination and may be
proved by EUS-FNA.
• Endosonographic staging examinations of pancreaticobili-
ary, esophageal, and gastric cancer should not be restricted to
locoregional (TN) staging; moreover, in every patient careful
inspection of potential sites of metastatic spread, in par-
ticular mediastinal and other nonregional lymph node sta-
tions, (left) liver lobe, (left) adrenal gland, and pancreas,
should be performed in addition. Ascites, pleural effusions,
and peritoneal or pleural nodules should be watched out for.
• EUS-guided ﬁne-needle biopsy (EUS-FNB) should be used
to prove distant metastasis, peritoneal carcinosis, or pleural
carcinosis in all cases in which other imaging methods
have failed, or biopsy guidance by TUS or CT is regarded
inappropriate or potentially unsafe.
• Penetration of the needle through obvious neoplastic tissue
in the gastrointestinal wall must be avoided.
• According to the rules of TNM-classiﬁcation,25,26 a positive
ﬁnding of EUS-FNB for distant metastases is classiﬁed pM1.
Conversely, a negative cytopathological ﬁnding is classiﬁed
cM0 unless, due to clinical and imaging ﬁndings, a high
suspicion of metastasis is maintained (in this case the
correct classiﬁcation is cM1).
• In cases with suspected distant malignant spread, EUS-FNB
should follow an inverse TNM-schedule. Particularly in a
patient with a pancreatic mass which is suspicious for
pancreatic cancer, a potential distant metastasis should be
sampled ﬁrst. If necessary, the same needle may be used
subsequently for biopsy of a locoregional lymph node or
of the pancreatic mass itself.
• EUS and EUS-FNB have a high yield for the detection and/
or proof of postoperative recurrence of pancreaticobiliary
and gastrointestinal cancers, including colorectal cancer.
Immunohistochemistry is helpful for differentiation
between recurrence of the previous cancer on the one hand
and a second malignant tumor on the other.
Complications and Risk Factors
The complication rate of EUS-FNB is approximately 1–2%.16
A systematic review demonstrated that EUS-FNB is ex-
ceptionally safe for mediastinal lymph nodes (complication
rate: 0.38%), abdominal masses (complication rate: 0.26%),
and adrenal gland biopsies (complication rate: 0%; only a few
case reports of complications). EUS-FNB had an associated
overall morbidity of 2.33% for liver lesions and 3.53% for
ascites.27 EUS-FNB of ascites carries a low but relevant risk of
peritonitis.28 Therefore, the authors propose peri-interven-
tional antibiotic treatment.27
Annotations
In all videos cephalad direction is displayed on the right side
of the screen (yellow marker). The following abbreviations are
used in images:
• c – Clinical (staging)
• CK – Cytokeratin
• CT – Computed tomography
• EGD – Esophagogastroduodenoscopy
• ERCP – Endoscopic retrograde cholangio-pancreaticography
• EUS – Endoscopic ultrasound
• M – Distant metastasis
• N – Nodal metastasis
• p – Pathological (staging)
• T – (primary) Tumor
Scripted Voiceover
Part 1
Time
(min:sec)
Voiceover text
00:00–00:21 Part 1 of the video demonstration describes the role of
endoscopic ultrasound (EUS) and EUS-guided ﬁne-
needle biopsy (FNB) for the diagnosis of distant
metastasis in primary staging of pancreaticobiliary and
upper gastrointestinal cancer.
00:22–00:52 Cytopathological proof of distant metastases dramatically
changes therapeutic management and prognosis of
patients with pancreaticobiliary and gastrointestinal
cancer. To avoid false-positive diagnoses, EUS-FNB
should follow an inverse TNM-schedule. Following this
sequence, the same needle may be used subsequently
for biopsy of a locoregional lymph node or of a potential
pancreatic primary itself.
00:53–01:20 The ﬁrst case describes a 78-year-old man presenting
with weight loss and abdominal pain. Transabdominal
ultrasound shows a large hypoechoic mass lesion of the
pancreatic tail and body, but no solid liver lesions.
The Role of Endoscopic Ultrasound in M-Staging of Gastrointestinal and Pancreaticobiliary Cancer106
(01:05) Computed tomography conﬁrms the large
pancreatic mass encasing the celiac trunk and hepatic
artery, but also detects several small hypodense liver
lesions, highly suspicious for metastases.
01:21–02:11 From a position in the upper gastric body longitudinal EUS
the huge hypoechoic mass lesion and adjacent
hypoechoic lymph nodes are shown. (01:37) Turning
the scope counterclockwise the left liver lobe is
visualized. Liver parenchyma is heterogeneous, and a
1 cm solid lesion is delineated very well. EUS-guided
ﬁne-needle biopsy is performed using a 22-Gauge
aspiration needle. Three needle passes are performed,
and the lesion is fanned by the needle several times.
02:12–02:48 Semi-liquid material is smeared onto glass slides, and
small tissue cores are ﬁxed in formaline solution. Both,
cytological and histological examinations give evidence
for metastasis of a poorly differentiated
adenocarcinoma. (02:36) In particular, periodic acid
Schiff-staining ﬁnely depicts the malignant inﬁltration of
liver tissue. Pretherapeutic tumor stage therefore is cT4
cN1 pM1.
02:49–03:12 The second case illustrates the potential of EUS to detect
and prove occult liver metastases. A 75-year-old patient
presented with obstructive jaundice caused by a small
mass lesion of the ampullary region. (03:08)
Endoscopic retrograde cholangiopancreaticography
(ERCP) was performed, and the distal bile duct stricture
was drained using a plastic endoprosthesis.
03:13–04:15 Longitudinal endoscopic ultrasound shows the
hypoechoic mass lesion of the papilla, slight dilatation
of the pancreatic duct, and effective drainage of the bile
duct. (03:31) Withdrawal of the scope to the stomach
allows visualization of the left liver lobe, showing a
small, subcentrimetric hypoechoic mass lesion, which
was not shown by ultrasound and CT previously.
(03:43) Using a 22-Gauge aspiration needle, EUS-
guided ﬁne-needle biopsy is performed. Several studies
have shown that EUS-guided biopsy of liver lesions is
effective and safe with a complication rate of
approximately 2.3%.
04:16–04:28 Histology of the small liver lesion proves metastatic
inﬁltration with an undifferentiated cancer.
04:29–06:13 A 58-year-old patient complains about vomiting, bloating,
and weight loss. Gastroscopy results in a diagnosis of
poorly differentiated cancer of the gastric antrum and
body. (04:45) CT shows marked thickening of the
gastric wall, but no liver metastases. (04:55) However,
enlarged mediastinal lymph nodes and a small nodule of
the right lung are found, suspicious for distal malignant
spread. (05:09) Longitudinal EUS shows malignant
inﬁltration involving all layers exceeding the muscularis
propria without penetrating the serosa, corresponding
to a tumor stage cT3. Large infracarinal lymph nodes
with focal hypoechoic inﬁltration are depicted and
sampled using a 22-Gauge aspiration needle. Care is
taken to target the small hypoechoic areas within the
lymph node, which are suspected to harbor small
metastatic inﬁltrations.
06:14–06:40 Histology shows anthracotic lymph node tissue and a so-
called anthracosis-granuloma, but no malignant
inﬁltration (06:24). However, smear cytology
demonstrates a group of atypical glandular epithelia.
This ﬁnding is indicative for mediastinal lymph node
metastasis, and pretherapeutic tumor classiﬁcation is
cT3 cN0 pM1.
06:41–07:05 Due to iron deﬁciency anemia and weight loss,
gastroscopy is performed on a 63-year-old female
patient. A tumor of the gastric cardia is found, and
endoscopic biopsy proves adenocarcinoma. Besides
wall thickening of the gastroesophageal junction CT
shows small cysts and two suspicious lesions of the left
liver lobe.
07:06–07:36 Longitudinal EUS is performed and shows inﬁltration
far beyond the gastroesophageal wall with penetration
of the gastric serosa and esophageal adventitia,
small amounts of ascites, and an adjacent lymph
node metastasis. Local tumor stage therefore is cT4a
cN1.
07:37–08:21 Moreover, EUS gives proof of solid liver lesions in the
vicinity of small liver cysts, which are harder compared
to liver parenchyma. Using a 22-Gauge aspiration
needle, a biopsy of the suspicious liver lesion is
performed.
08:22–08:54 Cytologic and histologic ﬁndings conﬁrm liver metastasis.
Pretherapeutic tumor stage therefore is cT4a cN1 pM1.
Palliative chemotherapy is initiated.
08:55–09:08 A 78-year-old male patient presents with weight loss and
vomiting. In gastroscopy a stenosing gastric cancer is
found. CT detects no liver metastases.
09:09–10:00 Longitudinal EUS shows thickening and inﬁltration of all
wall layers. There is high suspicion of subserosal
inﬁltration, but gastric serosa seems not to be
penetrated. This ﬁnding corresponds with local stage
T3, and – according to guidelines – perioperative
chemotherapy would be appropriate. However, there is
a small amount of ascites, and the perigastric ﬂuid is
not completely anechoic. (09:40) This ﬁnding is highly
suspicious for peritoneal metastasis. Proof of peritoneal
carcinosis would change the management of the patient
signiﬁcantly, indicating palliative surgery. However, in
this case EUS-guided ﬁne-needle aspiration is not suited
for proof of malignant ascites, because the needle would
penetrate the primary tumor, potentially being
contaminated by tumor cells. Therefore, in this case
staging laparoscopy is performed to prove the palliative
situation.
Part 2
Time (min:sec) Voiceover text
00:00–00:12 Beyond pretherapeutic M-staging, EUS and
EUS-FNA may play a pivotal role in detecting
and diagnosing recurrence or late distant
spread of gastrointestinal cancer. This role
is highlighted by the following case studies.
00:12–00:24 Five years after surgery for ampullary cancer,
a 72-year-old woman presents with weight
loss. Transabdominal ultrasound
demonstrates very small amounts of
ascites.
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00:25–00:55 EUS detects several hypoechoic lymph nodes
in the subdiaphragmal region in the
neighborhood of the left adrenal gland and
the celiac ganglia.
00:56–01:08 Traditional B-mode criteria are typical for
malignancy, and real-time elastography
supports the suspicion of malignant
lymph node inﬁltration by showing a hard
pattern.
01:09–01:24 EUS-guided biopsy is performed using a 22-
Gauge aspiration needle. Material is
obtained for smear cytology as well as for
histology.
01:25–01:45 The aspirate shows normal lymphocytes and
malignant inﬁltration of the lymph node by a
well-differentiated adenocarcinoma.
01:46–02:36 Turning the scope counterclockwise reveals
ascites and peritoneal nodules, which are
relatively hard. (02:00) Again, EUS-guided
biopsy is performed, targeting the peritoneal
nodule. In order to minimize ﬂuid aspiration,
no suction is applied. EUS-guided aspiration
of ascites carries a relevant risk of
peritonitis and therefore has an associated
overall morbidity of approximately 3.5%. To
prevent infection of ascites, in this case
intravenous antibiotics are administered at
the time of intervention.
02:37–03:22 Cytologic smears of ascites show papillary
groups of epithelial cancer cells. (02:49)
Moreover, small tissue cores obtained from
the peritoneal nodule prove peritoneal
carcinosis. (03:00) Immunostaining is
positive for cytokeratine 7. Therefore,
diagnosis in this case is late nodal and
peritoneal metastasis of ampullary cancer.
Palliative treatment is initiated.
03:23–03:46 A 76-year-old woman with a history of
colon cancer 7 years previously is admitted
to the hospital with hoarseness, acute
dyspnea and right femoral thrombosis.
(03:36) Chest CT not only detects
thromboembolic material with the
pulmonary arteries, but also enlarged
mediastinal lymph nodes.
03:47–03:58 Moreover, abdominal CT shows mass lesions
of the right iliac fossa and at the vaginal
stump 15 years after hysterectomy for large
uterine leiomyoma.
03:59–04:32 At the moment, there are various possible
diagnostic explanations for these diagnostic
ﬁndings, for example malignant
gynecological tumor with mediastinal lymph
node metastases or late mediastinal and
pelvic metastases of cecal cancer.
Longitudinal EUS reproduces the CT
ﬁndings of suspicious infracarinal
pathological lymph nodes (04:22). As
expected, these nodes are harder in
comparison with the surrounding
mediastinal tissue.
04:33–04:50 EUS-guided biopsy is performed using a 22-
Gauge standard aspiration needle. Of
course, heparin treatment has been
interrupted before.
04:51–05:32 In good accordance to CT, radial EUS of the
rectum shows the mass lesion of the vaginal
stump. However, it is not clear, whether this
lesion represents the primary tumor of the
mediastinal lymph node metastases or
rather a pelvic metastasis of the previous
cecal cancer. (05:21) Again, in elastography
this lesion codes blue, indicating a higher
stiffness compared with the surrounding
tissue.
05:33–05:58 After having changed the echoendoscope, we
perform a transrectal EUS-guided biopsy.
There is a lot of resistance to the 22-Gauge
needle; however, sufﬁcient material is
obtained for cytopathological examination.
Prophylactic antibiotics have been shown to
be dispensable in the case of transrectal
EUS-guided biopsy.
05:59–06:56 Cytological smears and tissue cores from the
mediastinal lymph nodes as well as from the
pelvic mass show malignant inﬁltration by
an adenocarcinoma. (06:22) Tumor cells
stain negative for cytokeratine 7 and TTF1,
(06:35) but positive for cytokeratine 20. This
is a typical immunophenotype of intestinal
adenocarcinoma, and diagnosis of late
pelvic and mediastinal metastases of cecal
adenocarcinoma is established.
06:57–07:40 The last case describes a 61-year-old male
patient who was treated 2 years previously
with perioperative chemotherapy and
surgery for locally advanced gastric cancer.
Regular follow-up detects a splenic mass
lesion. In abdominal and chest CT there is
no other suspicious lesion. (07:15) Because
of lung emphysema percutaneous biopsy is
considered to be risky, and therefore
longitudinal EUS is performed. From a
position within the jejunal pouch there is
direct endosonographic access to the
spleen. The splenic lesion is hypoechoic and
heterogeneous. Moreover, it is harder than
the surrounding splenic tissue. A malignant
splenic tumor is highly probable, and
metastasis of gastric cancer is suspected.
07:41–08:13 For EUS-guided biopsy we use the 22-Gauge
aspiration needle. Several case series have
shown EUS-guided biopsy of splenic lesions
to be a safe and effective technique. No
serious complications have been described.
With only one needle pass we are able to
harvest material, which is sufﬁcient for
cytological and histological examination.
08:14–08:59 Both smear cytology and histology show a
mixed population of lymphoid cells and
inﬁltration of poorly differentiated
adenocarcinoma within fragments.
Immunostaining for cytokeratins 7, 5 and 6,
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for p63 and for TTF1 is negative. (08:36)
However, the tumor cells stain positive for a
pancytokeratin marker and for the intestinal
marker cytokeratin 20. This constellation
conﬁrms the diagnosis of splenic metastasis
of gastric cancer. Consequently,
splenectomy and adjuvant chemotherapy
are planned.
09:00–09:30 if needed
longer (10:00)
In conclusion, despite its limited operation
range, EUS and EUS-guided ﬁne-needle
biopsy may add value to percutaneous
ultrasound and CT by detecting and proving
‘occult’ distant metastases and malignant
ascites in approximately 5–20% of cases of
pancreaticobiliary and upper gastrointestinal
tract cancer. To avoid false-positive
diagnoses, penetration of the aspiration
needle through neoplastic inﬁltrations of the
gastrointestinal wall must be avoided, and
EUS-guided ﬁne-needle biopsy should
follow an inverse TNM-schedule. Moreover,
EUS and EUS-guided ﬁne-needle biopsy play
an important role for the detection and
cytopathological proof of postoperative
recurrence of pancreaticobiliary and
gastrointestinal cancers.
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